SCHEMBL3495778

SCHEMBL3495778

COC(=O)c1ccc(CC(C)C)c(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.53
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 4/20 0.46
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA7 P43166 2/20 0.45
CA9 Q16790 2/20 0.45
CA14 Q9ULX7 2/20 0.45
XDH P47989 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
LMNA P02545 2/20 0.42
MAPT P10636 4/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13328614 0.86 CA12 (0.51) DPP4ALDH1A1CA12CA1CA2
SCHEMBL197186 0.84 DPP4 (0.49) DPP4KDM4EALDH1A1CA12CA1
SCHEMBL4123831 0.83 DPP4 (0.51) DPP4KDM4EALDH1A1CA12CA1
SCHEMBL21502002 0.83 MLYCD (0.50) DPP4ALDH1A1CYP1A2CYP2C19LMNA
SCHEMBL2538454 0.83 ALDH1A1 (0.47) DPP4KDM4EALDH1A1CA12CA1
SCHEMBL27150109 0.82 DPP4 (0.50) DPP4KDM4EALDH1A1CA12CA1
SCHEMBL3128273 0.82 EPHX2 (0.50) KDM4ELMNAHPGDMEN1HTT
SCHEMBL8251185 0.81 MAPT (0.54) KDM4EALDH1A1CA12CA1CA2
SCHEMBL13841059 0.81 KDM4E (0.57) DPP4KDM4EALDH1A1CA12CA1
SCHEMBL25017929 0.81 HRH4 (0.43) DPP4LMNAHPGDMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7659294-B2 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists MERCK & CO., INC. (US) 2010-02-09 US disclosed
US-20090042954-A1 2-(Aryl)Azacyclylmethyl Carboxylates, Sulfonates, Phosphonates, Phosphinates and Heterocycles as S1p Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-02-12 US disclosed
CN-101043887-A 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists MERCK & CO INC (US) 2007-09-26 CN disclosed
EP-1804793-A2 2-(ARYL)AZACYCLYLMETHYL CARBOXYLATES, SULFONATES, PHOSPHONATES, PHOSPHINATES AND HETEROCYCLES AS S1P RECEPTOR AGONISTS Merck & Co., Inc. (US) 2007-07-11 EP disclosed
WO-2006047195-A2 2-(ARYL)AZACYCLYLMETHYL CARBOXYLATES, SULFONATES, PHOSPHONATES, PHOSPHINATES AND HETEROCYCLES AS S1P RECEPTOR AGONISTS MERCK & CO., INC. (US) 2006-05-04 WO disclosed
WO-1994018168-A1 INDOLE DERIVATIVES AS 5-ALPHA-REDUCTASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042954-A1 2-(Aryl)Azacyclylmethyl Carboxylates, Sulfonates, Phosphonates, Phosphinates and Heterocycles as S1p Receptor Antagonists S1PR1, S1PR3, S1PR5 DPP4 1796/4885KDM4E 1251/4885ALDH1A1 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.